Bio-Rad Laboratories, Inc. (BIO)
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Symbol
- BIO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $10.13B
- 52 week range
- 236.73 - 396.23
Valuation
- Share price
- $378.88 (close of 2026-09-23)
- P/E (TTM)
- 45.92x
- Price to book
- 1.41x
- Price to free cash flow
- 28.70x
- Enterprise value
- $9.89B
- Book value per share
- $268.22
Price performance
| Period | Change |
|---|
| 1 day | +0.41% |
| 5 days | +0.23% |
| 1 month | -0.30% |
| 3 months | +40.16% |
| 6 months | +42.97% |
| Year to date | +25.05% |
| 1 year | +34.32% |
| 3 years | +7.32% |
| 5 years | -52.48% |
| 10 years | +134.83% |
| All time | +14758.04% |
Profitability and growth
- Return on equity
- 10.20%
- Return on invested capital
- 0.32%
- Return on assets
- 7.18%
- Return on capital employed
- 0.47%
- Gross margin
- 51.87%
- Net margin
- 29.42%
- EBITDA margin
- 8.23%
- Revenue growth
- 0.65%
- Net income growth
- 141.20%
- Free cash flow growth
- 29.35%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.48%
- Current ratio
- 3.14x
- Net debt to EBITDA
- -0.44x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.58B
- Cost of revenue
- $1.24B
- Gross profit
- $1.34B
- EBITDA
- $212.60M
- Net income
- $759.90M
- Earnings per share
- $27.87
- Research and development
- $275.60M
- Interest expense
- $49.00M
- Shares outstanding
- 27.26M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $2.58B | $1.34B | $759.90M | $27.87 |
| 2024-12-31 | $2.57B | $1.38B | $-1.84B | $-65.36 |
| 2023-12-31 | $2.67B | $1.43B | $-637.30M | $-21.82 |
| 2022-12-31 | $2.80B | $1.57B | $-3.63B | $-121.79 |
| 2021-12-31 | $2.92B | $1.64B | $4.25B | $142.61 |
| 2020-12-31 | $2.55B | $1.44B | $3.81B | $128.13 |
| 2019-12-31 | $2.31B | $1.26B | $1.76B | $58.93 |
| 2018-12-31 | $2.29B | $1.22B | $365.61M | $12.25 |
| 2017-12-31 | $2.16B | $1.19B | $122.25M | $4.12 |
| 2016-12-31 | $2.07B | $1.14B | $26.00M | $0.88 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 51.87% | 29.42% | 10.20% | 0.32% |
| 2024-12-31 | 53.73% | -71.86% | -28.07% | 4.28% |
| 2023-12-31 | 53.42% | -23.86% | -7.29% | 3.96% |
| 2022-12-31 | 55.93% | -129.45% | -37.73% | 5.24% |
| 2021-12-31 | 56.05% | 145.57% | 31.09% | 1.92% |
| 2020-12-31 | 56.49% | 149.84% | 38.57% | 2.31% |
| 2019-12-31 | 54.38% | 76.08% | 30.55% | 2.36% |
| 2018-12-31 | 53.43% | 15.97% | 9.09% | -3.25% |
| 2017-12-31 | 54.98% | 5.66% | 4.17% | 5.48% |
| 2016-12-31 | 55.04% | 1.26% | 1.01% | 2.31% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $1.54B | $1.20B |
| 2024-12-31 | $1.66B | $1.20B |
| 2023-12-31 | $1.61B | $1.20B |
| 2022-12-31 | $1.79B | $1.20B |
| 2021-12-31 | $869.92M | - |
| 2020-12-31 | $991.12M | - |
| 2019-12-31 | $1.11B | - |
| 2018-12-31 | $844.80M | - |
| 2017-12-31 | $754.98M | - |
| 2016-12-31 | $839.44M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $374.60M | $58.00M |
| 2024-12-31 | $289.60M | $62.30M |
| 2023-12-31 | $218.20M | $61.30M |
| 2022-12-31 | $81.60M | $60.90M |
| 2021-12-31 | $535.72M | $51.20M |
| 2020-12-31 | $476.41M | $41.60M |
| 2019-12-31 | $359.37M | $35.60M |
| 2018-12-31 | $155.67M | $27.80M |
| 2017-12-31 | $-7.20M | $23.40M |
| 2016-12-31 | $74.63M | $19.70M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $2.61
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-04 | Jun/2026 | $2.34 |
| 2026-04-30 | - | - |
| 2026-02-12 | - | - |
| 2025-10-29 | - | - |
| 2025-07-31 | - | - |
| 2025-07-30 | - | - |
| 2025-05-05 | - | - |
| 2025-05-01 | - | - |
Filings and sources
- Company website
- bio-rad.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades